Skip To Main Content
Ezgi Karaesmen Rizvi on Muck Rack

Ezgi Karaesmen Rizvi

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ezgi Karaesmen

Contact Ezgi Karaesmen, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Low-level Aurora kinase A amplification: CDK4/6 inhibitor resistance biomarker in hormone receptor-positive metastatic breast cancer

|
By Seth A. Wander, Emily Schultz, Agnieszka K. Witkiewicz, Georg F. Bischof, Erik S. Knudsen, Karthik V. Giridhar, Lisa D. Eli, Ezgi Karaesmen Rizvi, Roosheel Sandeep Patel
| Nature Verified
Abstract In this large, real-world, translational research cohort of 708 patients in the Tempus database who had hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) metastatic breast cancer with prior cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6i) exposure, low-level Aurora kinase A (AURKA) copy-number (CN) gain was common, occurring in 106/708 patients (15.0%).
Open in Who Shared Issue with article?
See all 1 articles